Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.

Shigellosis (bacillary dysentery) is a severe gastrointestinal infection with a global incidence of 90 million cases annually. Despite the severity of this disease, there is currently no licensed vaccine against shigellosis. Shigella’s primary virulence factor is its type III secretion system (T3SS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ti, Das, Sayan, Howlader, Debaki R., Jain, Akshay, Hu, Gang, Dietz, Zackary K., Zheng, Qi, Ratnakaram, Siva Sai Kumar, Whittier, Sean K., Varisco, David J., Ernst, Robert K., Picking, William D., Picking, Wendy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512073/
https://www.ncbi.nlm.nih.gov/pubmed/37744341
http://dx.doi.org/10.3389/fimmu.2023.1194912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512073/
https://www.ncbi.nlm.nih.gov/pubmed/37744341
http://dx.doi.org/10.3389/fimmu.2023.1194912

Ejemplares similares